Analysts Update Ratings and Price Targets for CG Oncology
Several financial institutions, including Wedbush, HC Wainwright, and RBC, updated their price targets and ratings for CG Oncology following recent clinical trial results.
Stocks · News reference
CG Oncology, Inc. reported its financial results for the third quarter ended September 30, 2026, and provided updates on its clinical pipeline.
Reference Details
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
Keep reading
Several financial institutions, including Wedbush, HC Wainwright, and RBC, updated their price targets and ratings for CG Oncology following recent clinical trial results.
CG Oncology reports Phase 3 data showing cretostimogene cuts bladder cancer recurrence risk by 68%, advancing two 2027 BLA filings.
U.S. stocks fell Monday as tech slid and manufacturing sentiment weakened; oil, gold and silver also declined, while TELUS and H World surged.
U.S. stocks fell, but H World Group surged 9.3% on strong Q3 results and raised guidance; several other stocks posted notable gains.
CG Oncology reported positive topline results from its Phase 3 PIVOT-006 trial evaluating cretostimogene grenadenorepvec in patients with intermediate-risk and high-grade Ta bladder cancer.
Filed: 2026-11-16 AccNo: 0001193125-26-462199 Size: 17 MB Item 7.01: Regulation FD Disclosure Item 8.01: Other Events Item 9.01: Financial Statements and Exhibits